MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Amgen Inc

Închisă

SectorSănătate

310.17 1.39

Rezumat

Modificarea prețului

24h

Curent

Minim

305.51

Maxim

313.95

Indicatori cheie

By Trading Economics

Venit

-2.2B

627M

Vânzări

586M

9.1B

P/E

Medie Sector

41.156

63.778

EPS

5.31

Randament dividend

3.06

Marjă de profit

6.901

Angajați

28,000

EBITDA

-517M

2.9B

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+8.74% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

3.06%

2.39%

Următoarele câștiguri

1 mai 2025

Data viitoare de dividende

6 iun. 2025

Următoarea dată ex-dividende

16 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

14B

167B

Deschiderea anterioară

308.78

Închiderea anterioară

310.17

Sentimentul știrilor

By Acuity

50%

50%

180 / 386 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bearish Evidence

Amgen Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

4 feb. 2025, 21:29 UTC

Câștiguri

Amgen 4Q Sales Up 11% as Ten Products Post Double-Digit Gains

30 oct. 2024, 20:18 UTC

Câștiguri

Amgen Posts Higher 3Q Sales on Strong Demand

28 feb. 2025, 12:00 UTC

Top știri

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

4 feb. 2025, 21:02 UTC

Câștiguri

Amgen 4Q SAles Included $1.2 B of Sales From Rare Disease Products >AMGN

4 feb. 2025, 21:01 UTC

Câștiguri

Amgen 4Q Worldwide Neulasta Sales $98M >AMGN

4 feb. 2025, 21:01 UTC

Câștiguri

Amgen 4Q Worldwide Enbrel Sales $1.01B >AMGN

4 feb. 2025, 21:01 UTC

Câștiguri

Amgen 4Q Worldwide Prolia Sales $1.17B >AMGN

4 feb. 2025, 21:01 UTC

Câștiguri

Amgen Sees FY Rev $34.3B-$35.7B >AMGN

4 feb. 2025, 21:01 UTC

Câștiguri

Amgen 4Q Adj EPS $5.31 >AMGN

4 feb. 2025, 21:01 UTC

Câștiguri

Amgen 4Q Worldwide XGEVA Sales $561M >AMGN

4 feb. 2025, 21:01 UTC

Câștiguri

Amgen Sees FY EPS $10.89-EPS $12.14 >AMGN

4 feb. 2025, 21:01 UTC

Câștiguri

Amgen Sees FY Adj EPS $20.00-Adj EPS $21.20 >AMGN

4 feb. 2025, 21:01 UTC

Câștiguri

Amgen 4Q Rev $9.1B >AMGN

4 feb. 2025, 21:01 UTC

Câștiguri

Amgen 4Q EPS $1.16 >AMGN

4 feb. 2025, 21:01 UTC

Câștiguri

Amgen 4Q Net $627M >AMGN

28 ian. 2025, 10:30 UTC

Top știri

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

27 dec. 2024, 07:00 UTC

Câștiguri

3 Healthcare Stocks to Buy for a 2025 Rebound -- Barrons.com

23 dec. 2024, 15:04 UTC

Top știri

Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark. -- Barrons.com

13 dec. 2024, 14:53 UTC

Top știri

Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling. -- Barrons.com

30 nov. 2024, 12:00 UTC

Top știri

Eli Lilly and Novo Nordisk's Obesity Moat Just Got Stronger -- Heard on the Street -- WSJ

26 nov. 2024, 12:34 UTC

Top știri

Amgen Drug Cut Weight in Closely Watched Study -- WSJ

4 nov. 2024, 12:00 UTC

Top știri

Big Pharma's Obesity Bonanza Faces New Tests -- Heard on the Street -- WSJ

30 oct. 2024, 20:02 UTC

Câștiguri

Amgen 3Q Sales From Rare Disease Products $1.2B >AMGN

30 oct. 2024, 20:02 UTC

Câștiguri

Amgen CEO: Strong Growth in Sales, Earnings in 3Q Reflects Momentum Being Built Throughout Business>AMGN

30 oct. 2024, 20:02 UTC

Câștiguri

Amgen: 2024 Buybacks Not to Exceed $500M>AMGN

30 oct. 2024, 20:02 UTC

Câștiguri

Amgen 3Q Worldwide XGEVA Sales $541M >AMGN

30 oct. 2024, 20:02 UTC

Câștiguri

Amgen 3Q Worldwide Prolia Sales $1.05B >AMGN

30 oct. 2024, 20:01 UTC

Câștiguri

Amgen 3Q Worldwide Enbrel Sales $825M >AMGN

30 oct. 2024, 20:01 UTC

Câștiguri

Amgen 3Q Worldwide XGEVA Sales $541M >AMGN

30 oct. 2024, 20:01 UTC

Câștiguri

Amgen 3Q Worldwide Neulasta Sales $110M >AMGN

Comparație

Modificare preț

Amgen Inc Așteptări

Obiectiv de preț

By TipRanks

8.74% sus

Prognoză pe 12 luni

Medie 332.43 USD  8.74%

Maxim 389 USD

Minim 280 USD

În baza a 18 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAmgen Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

18 ratings

11

Cumpărare

6

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

304.35 / 315.75Suport & Rezistență

Termen scurt

Bearish Evidence

Termen mediu

Bullish Evidence

Termen lung

Strong Bullish Evidence

Sentiment

By Acuity

180 / 386 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.